Science & Enterprise subscription

Follow us on Twitter

  • A company developing a treatment for Covid-19 infections taken as a tablet instead of infusion issued its initial p… https://t.co/iByygVnB9U
    about 16 hours ago
  • New post on Science and Enterprise: Covid-19 Drug Biotech Raises $300M in IPO https://t.co/zwkRakiFk5 #Science #Business
    about 16 hours ago
  • The Food and Drug Administration plans to use organ-on-chip models to test mechanisms for preventing Covid-19 infec… https://t.co/9zAfSK9Nnt
    about 21 hours ago
  • New post on Science and Enterprise: FDA to Use Lung Chip Model for Covid-19 Testing https://t.co/YGwasY1UUJ #Science #Business
    about 21 hours ago
  • Interim results from a clinical trial show a synthetic antibody drug reduces viral burden and medical visits among… https://t.co/bm7JdQ83hT
    about 2 days ago

Please share Science & Enterprise

Patent Granted for Lung Disorder Treatment

Illustration of lungs (Mikael Häggström/Wikimedia Commons)

(Mikael Häggström/Wikimedia Commons)

Discovery Laboratories Inc., a biotechnology company in Warrington, Pennsylvania, said today the company received a U.S. patent for its treatment of pulmonary inflammation. The patent — number 7,863,241 — expires in 2023.

Discovery Labs says the patent covers its KL4 peptide (also known as sinapultide), an engineered pulmonary surfactant that lowers surface tension and promote oxygen exchange. The patented treatment delivers an array of protease inhibitors, administered as either a liquid or aerosol, for treating pulmonary inflammation.

The company credits Charles Cochrane, co-founder of The Scripps Research Institute, as the original inventor of Discovery Labs’ surfactant technology. The Scripps Research Institute has granted Discovery Labs exclusive licensing rights for this patent.

*     *     *

Comments are closed.